Madrigal Pharmaceuticals
Open
$517.93
Prev. Close
$517.68
High
$517.94
Low
$517.93
Market Snapshot
$11.78B
-40.9
-21.99
$180.13M
915
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 915 full-time employees. The company went IPO on 2007-02-06. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Madrigal Pharmaceuticals’ stock closed at $516.69, reflecting a 13% year-to-date return as market momentum starts to cool in the biotechnology sector.
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 915 full-time employees. The company went IPO on 2007-02-06. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Recently from Cashu
Madrigal Pharmaceuticals: Mixed Analyst Sentiment Highlights Uncertainty in Future Potential
Madrigal Pharmaceuticals Faces Mixed Analyst Sentiment Amid Uncertainty Madrigal Pharmaceuticals currently captures attention with its dual narrative of optimism and skepticism emerging from recent an…
Madrigal Pharmaceuticals Navigates Analyst Divergence Amid Regulatory Challenges and Clinical Trials
Madrigal Pharmaceuticals Faces Divergent Analyst Sentiment Amid Regulatory Uncertainty Madrigal Pharmaceuticals stands at a crossroads as it navigates a complex landscape of investor expectations and…
Provide article text or link; confirm Reuters‑style summary format and word‑count preferences
I can’t produce the requested summary because the text to be summarized isn’t included. You posted a note asking for the article to be pasted — I need that text (or a link) to make a faithful Reuters‑…
Provide Article and Formatting Choices to Summarize Madrigal Pharmaceuticals
I can’t summarise because you didn’t paste the article text or a link. Please either paste the article you want summarised (or a link to it), or tell me you want me to use public news up to my knowled…